グリメピリドの血糖改善効果に及ぼす患者背景要因としてのpreLPLの有用性

概要

論文の詳細を見る
The administration of glimepiride brings about a decrease in blood glucose through an insulin secretion promoting action and an insulin resistance improving action. However, there has been no definite factor for predicting whether it will be effective in doing this or not. Thus in order to use glimepiride in a better way, we decided to evaluate the usefulness of preheparin serum lipoprotein lipase mass (preLPL) in determining insulin susceptibility, a patient background factor that influences the effectiveness of glimepiride in improving blood glucose. Changes in body weight, blood glucose and lipid metabolism were investigated during administration of glimepiride in 52 patients with Type 2 diabetes who visited our clinic during a 6 month period, when the dose was 3 mg/day. After six months of administering glimepiride, preLPL had increased by 20 ng/dL (p<0.05). The background factors found to contribute most significantly to improving blood glucose levels were HbA_<lc> greater than 8% (p<0.01) and preLPL below 50 ng/dL (p<0.05). These results suggest that the preLPL level would be a useful background factor in predicting the efficacy of glimepiride in improving blood glucose.
日本医療薬学会の論文
2004-12-10